scholarly journals Opposite effects of interleukin-4 and interleukin-10 on nitric oxide production in murine macrophages

1996 ◽  
Vol 5 (2) ◽  
pp. 110-112 ◽  
Author(s):  
A. Maru ◽  
S. K. Jackson
1999 ◽  
Vol 48 (12) ◽  
pp. 643-650 ◽  
Author(s):  
Y. Nemoto ◽  
T. Otsuka ◽  
H. Niiro ◽  
K. Izuhara ◽  
K. Yamaoka ◽  
...  

1996 ◽  
Vol 170 (1) ◽  
pp. 34-40 ◽  
Author(s):  
Hong Jiang ◽  
John A. Rummage ◽  
Charles A. Stewart ◽  
Mary J. Herriott ◽  
Irina Kolosova ◽  
...  

1997 ◽  
Vol 20 (4) ◽  
pp. 435-437 ◽  
Author(s):  
Kiyoshi TERAWAKI ◽  
Mitsuhiko NOSE ◽  
Toshiya KONDO ◽  
Keisuke KOJIMA ◽  
Hajime MIZUKAMI ◽  
...  

1997 ◽  
Vol 60 (7) ◽  
pp. 708-711 ◽  
Author(s):  
Wen-Fei Chiou ◽  
Yen-Jen Sung ◽  
Jyh-Fei Liao ◽  
Andrew Yau-Chik Shum ◽  
Chieh-Fu Chen

1996 ◽  
Vol 135 (3) ◽  
pp. 374-378 ◽  
Author(s):  
Renato Laffranchi ◽  
Giatgen A Spinas

Laffranchi R, Spinas GA. Interleukin 10 inhibits insulin release from and nitric oxide production in rat pancreatic islets. Eur J Endocrinol 1996;135:374–8. ISSN 0804–4643 Interleukin 10 was found to prevent cytokine-induced nitric oxide production in murine macrophages. Because, in rat islets, interleukin 1β induces β-cell dysfunction, mainly due to overproduction of nitric oxide, we studied if this effect could be counteracted by interleukin 10. Rat pancreatic islets were cultured for 24 h in the presence or absence of 0.02–20 ng/ml recombinant human interleukin 10. Interleukin 10 dose-dependently inhibited insulin secretion with maximal inhibition (27 ±4%, p < 0.05) at 2 ng/ml without impairment of islet cell viability. However, incubation of pancreatic islets with interleukin 10 resulted in a 61.5% decrease of nitric oxide production. Co-incubation of islets with interleukin 10 (2 ng/ml) and recombinant human interleukin 1β (0.15 ng/ml) resulted in a more pronounced suppression of basal insulin release than with interleukin 1β alone (55 ± 3.6% vs 44 ± 3.6% with interleukin 1β alone, p < 0.05) but did not reduce interleukin 1β-stimulated NO production or reverse the effect of interleukin 1β on cell viability. Thus, in pancreatic islets interleukin 10 is not capable of counteracting the interleukin 1β-induced β-cell dysfunction, but rather enhances the inhibitory effect of interleukin 1β by a different mechanism. Renato Laffranchi, Division of Endocrinology and Metabolism, Department of Internal Medicine, University Hospital, Rämistrasse 100, CH-8091 Zürich, Switzerland


Sign in / Sign up

Export Citation Format

Share Document